Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ursodeoxycholic acid for primary sclerosing cholangitis.

O Chazouillères1, R Poupon, J P Capron

  • 1Hôpital Saint-Antoine, Paris, France.

Journal of Hepatology
|July 1, 1990
PubMed
Summary

Ursodeoxycholic acid (UDCA) treatment improved fatigue and itching in primary sclerosing cholangitis (PSC) patients. This 6-month study showed significant reductions in liver enzymes, suggesting UDCA is a promising therapy for PSC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.

Journal of viral hepatitis·2016
Same author

The impact of the prevention programme of hepatitis C over more than a decade: the French experience.

Journal of viral hepatitis·2009
Same author

[Centenary].

Gastroenterologie clinique et biologique·2009
Same author

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Journal of viral hepatitis·2006
Same author

[Diagnosis of spontaneous ascites infection in patients with cirrhosis: reagent strips].

Presse medicale (Paris, France : 1983)·2005
Same author

Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment.

Alimentary pharmacology & therapeutics·2005

Area of Science:

  • Hepatology
  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic liver disease with limited treatment options.
  • Fatigue and pruritus are common debilitating symptoms in PSC patients.
  • Ursodeoxycholic acid (UDCA) is a bile acid with potential therapeutic benefits in cholestatic liver diseases.

Purpose of the Study:

  • To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC).
  • To assess the impact of UDCA on clinical symptoms and biochemical markers of liver injury in PSC.

Main Methods:

  • Prospective evaluation of 15 PSC patients treated with UDCA (750-1250 mg/day) for 6 months.
  • Assessment of clinical symptoms (fatigue, pruritus) and serum liver enzymes (alkaline phosphatase, gamma-glutamyl transpeptidase, alanine aminotransferases).

Related Experiment Videos

  • Inclusion of patients with and without associated inflammatory bowel disease.

    • Main Results:

    • Significant reduction in the proportion of patients experiencing fatigue (60% to 20%) and pruritus (33% to 20%).
    • Marked decrease in serum alkaline phosphatase, gamma-glutamyl transpeptidase, and alanine aminotransferases levels (p < 0.001).
    • Discontinuation of UDCA led to worsening of liver test results in three patients, indicating treatment dependency.

    Conclusions:

    • Six months of UDCA treatment resulted in significant clinical and biochemical improvements in PSC patients.
    • UDCA appears to be an effective and safe treatment option for PSC.
    • The findings support the need for a controlled therapeutic trial to further validate UDCA's efficacy in PSC.